<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00447460</url>
  </required_header>
  <id_info>
    <org_study_id>CSM/EICH2005</org_study_id>
    <secondary_id>EudraCT Number: 2005-003674-14</secondary_id>
    <nct_id>NCT00447460</nct_id>
  </id_info>
  <brief_title>Treatment of Refractory (Acute or Chronic) Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell</brief_title>
  <official_title>A Phase I/II Trial in Treating Patients With Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Salamanca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Salamanca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial based on the use of a new therapeutic strategy (MSC infusion) for the
      treatment of patients who have developed a GVHD refractory to the usual therapeutic measures
      after undergoing an allogenic hematopoietic stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, single dose study of allogenic mesenchymal stem cell (1-2 x 10^6
      MSC/Kg recipient´s bodyweight).

      MSC will be infused, by a central venous catheter, to patients diagnosed with GVHD refractory
      to first-line or subsequent treatment.

      All patients will receive the same treatment. MSC suspension will be obtained from the bone
      marrow aspiration of a family donor and expanded in-vitro in a specific culture medium with
      autologous donor´s serum and with no animal-derived products.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety/efficacy of expanded in-vitro allogenic mesenchymal stem cell infusion in patients developing a GVHD refractory to the usual therapeutic measures after undergoing an allogeneic hematopoietic stem cell transplant.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy will be evaluated in terms of GVHD response.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety will be evaluated in terms of incidence of adverse events and toxicities related to the administration of MSC.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of infectious complications after MSC infusion.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyse the influence of MSC infusion on the posttransplant relapse risk of the base disease.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the influence of MSC infusion on DFS and OS.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine MSC grafted into the bone marrow (or in other organs).</measure>
  </secondary_outcome>
  <enrollment>15</enrollment>
  <condition>Graft-vs-Host Disease (GVHD)</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mesenchymal stem cell (MSC)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hematological malignancies who had been undergone an allogenic
             hematopoietic stem cell transplant and diagnosed with GVHD refractory to a usual
             treatment.

          -  Adequate cardiac function with no evidence of uncontrolled high blood
             pressure,congestive heart failure, angina pectoris, acute myocardial infarction within
             6 months prior to the process.

          -  Adequate pulmonary function with no evidence of chronic obstructive or severe
             restrictive pulmonary disease.

          -  Patients with ages between 18 and 65 years.

          -  Signature of informed consent form is required to be done by patient and donor.

        Exclusion Criteria:

          -  Patients whose hematopathology has not been controlled by the transplant or is in
             progress.

          -  Patients with bacterial, viral or fungal infection not being controlled with the
             adequate treatment.

          -  Patients with an inadequate cardiac or pulmonary function.

          -  Patients who, in the investigator´s point of view, are not in situation to tolerate
             the treatment.

          -  Patients who do not have the required donor (HLA-identical sibling donor and not
             HLA-identical sibling donor).

          -  Pregnant females or childbearing potential who are not on adequate contraceptive
             measures.

          -  Patients &lt;18 or &gt;65 years.

          -  Patients who do not sign the informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Consuelo del Cañizo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Haematology Service, University Hospital of Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José A Pérez-Simón, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haematology Service, University Hospital of Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Varcárcel Ferrerías, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haematology Service, Santa Creu i Sant Pau Hospital, Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Martínez Muñoz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haematology Service, Clinic i Provincial Hospital, Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Rifón Roca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haematology Service, University Clinic of Navarra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mercedes Comas, CRA</last_name>
    <phone>+(034)915545476</phone>
    <phone_ext>29</phone_ext>
    <email>mercedes.comas@logitest.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Clinic of Navarra</name>
      <address>
        <city>Navarra</city>
        <state>Pamplona</state>
        <zip>31080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José Rifón Roca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Creu i Sant Pau Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Varcárcel Ferrerías, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic i Provincial Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carmen Martínez Muñoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Consuelo del Cañizo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José A Pérez-Simón, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2007</study_first_submitted>
  <study_first_submitted_qc>March 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2007</study_first_posted>
  <last_update_submitted>March 20, 2007</last_update_submitted>
  <last_update_submitted_qc>March 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2007</last_update_posted>
  <keyword>Graft-vs-host disease (GVHD)</keyword>
  <keyword>Mesenchymal stem cell (MSC)</keyword>
  <keyword>Allogeneic hematopoietic stem cell transplant</keyword>
  <keyword>Allotransplant</keyword>
  <keyword>Allogenic</keyword>
  <keyword>Refractory</keyword>
  <keyword>CSM/EICH2005</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

